Immunomedics, Inc. has been issued U.S. patent no. 8,574,575 for “RS7 Antibodies.” This patent relates to methods of use of the company’s proprietary TROP-2 antibody. The allowed claims cover the use of IMMU-132, a SN-38 conjugate of TROP-2, for the treatment of cancer. TROP-2 is a receptor expressed by many human tumors, such as cancers of the breast, cervix, colon and rectum, kidney, liver, lung, ovary, pancreas, and prostate, but with only limited expression in normal human...